Download the ESMO 2012 Abstract Book - Oxford Journals

More documents

Recommendations

Info

Annals of Oncology deaths occurred. Prospective studies to evaluate Chemo following Ra-223 are warranted. Ra-223 + BSC Placebo + BSC Parameter (n = 90) (n = 54) Median time to Chemo; days (range) 79.0 (2–667) 64.5 (2–448) Median duration Chemo; days (range) 117.5 (1–809) 112.5 (1–863) Chemo = docetaxel; n (%) 63 (70.0) 39 (72.2) Docetaxel daily dose (mg); n 22 17 Mean (SD) 97.8 (41.6) 102.7 (46.3) Median (min-max) 92.5 (35-150) 120.0 (30-165) Deaths on Chemo; n (%) 13 (14.4) 8 (14.8) Cause: PC and skeletal mets (± other mets) 9 (10.0) 7 (13.0) PC with other mets (or mets not specified) 3 (3.3) 0 (0) Cerebral hemorrhage due to trauma Cardiopulmonary failure 1 (1.1) 0 (0) 0 (0) 1 (1.1) Deaths within 30 days post Chemo; n (%) 5 (5.6) 2 (3.7) Cause: PC and skeletal mets (± other mets) 3 (3.3) 2 (3.7) Bronchopneumonia Respiratory failure + pulmonary edema 1 (1.1) 1 (1.1) 0 (0) 0 (0) Neutrophils; (Absolute) (x10^9/L) 88 3.6 (0.9-26.0) 47 49 4.6 (1.9-16.4) 30 Baseline, n Median (min-max) 4.4 (0.5-24.4) 41 5.7 (1.6-13.1) 19 Month 2, n Median (min-max) 3.8 (1.3-10.8) 23 4.6 (1.1-8.9) 12 Month 4, n Median (min-max) 3.5 (0.5-6.3) 12 4.7 (1.5-12.2) 7 Month 6, n Median (min-max) 3.5 (1.9-9.4) 13 3.9 (3.0-6.4) 8 4.6 Month 8, n Median (min-max) 3.6 (1.1-8.9) 8 (3.0-8.5) 6 5.6 Month 10, n Median (min-max) Month 12, n Median (min-max) 5.0 (2.5-7.1) (2.8-8.9) BSC, best standard of care; Chemo, cytotoxic chemotherapy; mets, metastases; PC, prostate cancer Disclosure: O. Sartor: O. Sartor has served in a consultant or advisory role for Algeta ASA and Bayer. S. Nilsson: S. Nilsson has served in a consultant or advisory role for Algeta ASA. N. Vogelzang: N. Vogelzang has served in a consultant or advisory role for and has received grant/research support from Algeta ASA and Bayer. C.G. O’Bryan-Tear: C.G. O’Bryan-Tear is employed by and has an ownership interest in Algeta ASA. K. Staudacher: K. Staudacher is employed by and has an ownership interest in Algeta ASA. J.E. Garcia-Vargas: J. Garcia-Vargas is employed by Bayer HealthCare Pharmaceuticals. J. Zou: J. Zou is employed by Bayer HealthCare Pharmaceuticals. C. Parker: C. Parker has served in a consultant or advisory role for Algeta ASA (uncompensated) and Bayer. All other authors have declared no conflicts of interest. 937P DENOSUMAB IN PATIENTS WITH METASTATIC PROSTATE CANCER PREVIOUSLY TREATED WITH DENOSUMAB OR ZOLEDRONIC ACID: 2-YEAR OPEN-LABEL EXTENSION PHASE RESULTS FROM THE PIVOTAL PHASE 3 STUDY K. Fizazi 1 , J.E. Brown 2 , M. Carducci 3 , N.D. Shore 4 , P. Sieber 5 , F. Kueppers 6 , L. Karsh 7 ,R.Wei 8 , C. Goessl 9 1 Cancer Medicine, Institut Gustave Roussy, University of Paris Sud, Villejuif, FRANCE, 2 Medical Oncology, Cancer Research UK Clinical Centre, Universities of Leeds/Sheffield, Leeds, UNITED KINGDOM, 3 Kimmel Cancer Center, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, UNITED STATES OF AMERICA, 4 Urology, Carolina Urologic Research Center, Myrtle Beach, SC, UNITED STATES OF AMERICA, 5 Urology and Urological Surgery, Urological Associates of Lancaster, Ltd., Lancaster, PA, UNITED STATES OF AMERICA, 6 Urology, Urology Associates, Christchurch, NEW ZEALAND, 7 Clinical Research Department, The Urology Center of Colorado, Denver, CO, UNITED STATES OF AMERICA, 8 Global Biostatistical Science, Amgen Inc., Thousand Oaks, CA, UNITED STATES OF AMERICA, 9 Clinical Development, Amgen Inc., Thousand Oaks, CA, UNITED STATES OF AMERICA Background: In a phase 3, randomized, double-blinded (DB) trial (NCT00321620), subcutaneous (SC) denosumab prevented skeletal-related events (SRE) more effectively compared with intravenous (IV) zoledronic acid (ZA) in men with castration-resistant prostate cancer (CRPC) and bone metastases (Fizazi K et al., Lancet 2011). As a result, all patients (pts) remaining on study were offered open-label (OL) denosumab in a pre-specified 2-year extension phase. Materials and methods: Pts (n = 1901) with CRPC metastatic to bone received either SC denosumab 120 mg and IV placebo or IV ZA 4 mg (adjusted for renal function) and SC placebo Q4W in the DB treatment phase. OL denosumab Q4W was offered for up to 2 years to pts remaining on study. Pts declining OL treatment were followed for survival for up to 2 years after their last dose of investigational product in the DB treatment phase. Results: Of 323 pts completing the DB phase, 153 (87.4%) who were randomized to denosumab (here referred to as DD pts) and 128 (86.5%) randomized to ZA (here referred to as ZD pts) continued in the OL phase. Demographics were balanced between groups. Cumulative median (Q1, Q3) denosumab exposure over the entire study for DD pts was 12.0 (5.6, 21.3) months (range: 0.1 to 67.2 months). Overall, adverse events (AEs) were comparable between groups (n = 138/147 [93.9%] DD pts; n = 105/118 [89.0%] ZD pts). Twelve pts in the DD group and 7 pts in the ZD group developed osteonecrosis of the jaw (ONJ) in the OL phase, resulting in a cumulative ONJ incidence for the entire study of 3.8% for DD pts and 2.2% for ZD pts. Hypocalcemia AEs during the OL phase were balanced between groups (n = 8 DD pts; n = 5 ZD pts). Serious AEs were reported in 78 (53.1%) DD pts and 63 (53.4%) ZD pts. Median (95% CI) overall survival over the entire study was similar between groups: 19.4 months (17.8 to 21.0) for DD pts, 19.3 months (18.0 to 20.6) for ZD pts. Conclusion: This two-year OL extension treatment phase confirmed the long-term safety profile of denosumab in pts with prostate cancer metastatic to bone who received denosumab for up to 5.6 years or who switched from ZA to denosumab. Disclosure: K. Fizazi: Consultant/advisor: Amgen, Novartis, J.E. Brown: Advisory Board Member: Amgen, Novartis, Bristol Myers Squibb Corporate Sponsored Research: Novartis Other Substantive Relationships: Consultant, Amgen, M. Carducci: Consultant/advisor: Amgen, N.D. Shore: Consultant/Advisor: Amgen, Astellas, Bayer, Dendreon, Janssen, Medivation, Sanofi Corporate Sponsored Research: Amgen, Astellas, Bayer, Dendreon, Janssen, Medivation, Sanofi, Active Biotech, BMS, Millenium, Oncogenix, Progenics, BN Immunotherapeutics, P. Sieber: Other substantive relationships: consultant, speaker: Amgen, R. Wei: Employee and stockholder: Amgen, C. Goessl: Employee and stockholder: Amgen. All other authors have declared no conflicts of interest. 938P ANDROGEN DEPRIVATION AND RADIATION WITH HELICAL TOMOTHERAPY TO METASTASES IN PATIENTS WITH OLIGOMETASTATIC HORMONE - SENSITIVE PROSTATE CANCER P. Twardowski 1 ,W.Ye 2 ,S.Pal 1 , C. Arbayo 2 , M. Junqueira 1 , P. Tryon 1 , J. Wong 3 1 Medical Oncology and Experimental Therapuetics, City of Hope Cancer Center, Duarte, CA, UNITED STATES OF AMERICA, 2 Biostatistics, City of Hope Cancer Center, Duarte, CA, UNITED STATES OF AMERICA, 3 Radiation Oncology, City of Hope Cancer Center, Duarte, CA, UNITED STATES OF AMERICA Background: Metastatic prostate cancer (PC) is treated with androgen deprivation therapy (ADT) and subsequent treatments are employed only after the development of castration resistance. We hypothesized that treatment of oligometastases with external beam radiation therapy (EBRT) concurrent with ADT will be feasible and safe and may provide therapeutic benefit by more effective reduction in the tumor burden. Methods: Patients (pts) with hormone sensitive PC (HSPC) and 1-5 metastases (mts) detected by bone scan and CT scan were treated with 36 weeks of LHRH agonist combined with bicalutamide and EBRT up to 45 Gy to all visible metastatic sites. Seventeen pts (59%) who had no prior therapy of the primary tumor, also received up to 78 Gy to the prostate. Primary objectives were time to treatment failure (TTF) and toxicity. TTF was calculated from the end of therapy until PSA reached pre-treatment level or 10 (whichever was lower) or radiographic progression or until ADT was restarted. Results: Twenty nine pts were treated. Median number of mts was 1. Median Gleason score was 8 (range 5-10). Median baseline PSA was 11.4 (range 1-74.5). Twenty one pts (72%) had bone mts, 13 pts (45%) had lymph node (LN) mts and 8 pts (28%) had mts limited to pelvic LNs. Median follow up was 25.7 months (range 13.4-61.4). Grade 3 toxicities included diarrhea (7%), urinary frequency (3%), renal insufficiency (3%). Twenty five pts (86%) reached PSA nadir of
939P NEOADJUVANT SIPULEUCEL-T IN LOCALIZED PROSTATE CANCER: EFFECTS ON IMMUNE CELLS WITHIN THE PROSTATE TUMOR MICROENVIRONMENT L. Fong1 , V. Weinberg1 , S. Chan1 , J. Corman2 , C. Amling3 , R.A. Stephenson4 , J. Simko1 , R.B. Sims5 , P. Carroll1 , E.J. Small1 1 Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, UNITED STATES OF AMERICA, 2 Surgery, Virginia Mason Medical Center, Seattle, WA, UNITED STATES OF AMERICA, 3 Urology, Oregon Health & Science University, Portland, OR, UNITED STATES OF AMERICA, 4 Urology, University of Utah, Salt Lake City, UT, UNITED STATES OF AMERICA, 5 Clinical Affairs, Dendreon Corporation, Seattle, WA, UNITED STATES OF AMERICA Background: Sipuleucel-T is an FDA-approved autologous cellular immunotherapy for patients with asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer (mCRPC). To date, studies of sipuleucel-T in patients with mCRPC have studied immune response in peripheral blood. The immune effects of sipuleucel-T in prostatic cancer tissue are unknown. Methods: NeoACT (P07-1; NCT00715104) is an open-label, Phase 2 study of patients with localized prostate cancer who received sipuleucel-T prior to radical prostatectomy (RP) to examine the immunologic effects of treatment on prostate tissue. Patients received 3 infusions of sipuleucel-T at approximately 2-week intervals, beginning 6-7 weeks prior to RP, and post-RP are being followed for immune response. The primary endpoint was the change in the frequency of lymphocytes between prostate biopsies (pre-treatment) and RP tissue (post-treatment), as assessed by immunohistochemistry (IHC). Results: Of the 42 enrolled patients (median age 61 years, all ECOG = 0, Gleason Sum: ≤6 = 24%, 7 = 43%, ≥8 = 33%), 38 received all 3 pre-RP sipuleucel-T infusions and were evaluable by IHC. Treatment-related AEs were manageable and transient. Sipuleucel-T did not appear to affect operative complications, procedure time, or estimated blood loss. Frequent events (>10% of patients) that occurred ≤1 day after infusion were fatigue, headache, and myalgia. Significant increases (>3 fold) in infiltrating CD3 + , CD3 + /CD4 + , and CD3 + /CD8+ T cell populations were observed at the tumor rim (where benign and malignant glands interface), compared with the pretreatment biopsy (all p = 0.0001). CD3 + /CD4 + /FoxP3+ cells were also increased at the tumor rim (∼2-fold; P = 0.005), but represented a small proportion of the observed T cells. This level of T cell infiltration was not seen in a cohort of 12 concurrent cases that did not receive neoadjuvant treatment. Conclusions: Neoadjuvant sipuleucel-T treatment is associated with an increased frequency of T cells in the prostate at the interface of the benign and malignant glands. These data demonstrate that sipuleucel-T can modulate the presence of lymphocytes at prostate cancer tissue in vivo. Disclosure: L. Fong: Research funding from Dendreon. R.B. Sims: Employee and stockholder of Dendreon. P. Carroll: Honoraria from Takeda. Research funding from Myriad and Abbot, E.J. Small: Honoraria from Dendreon. All other authors have declared no conflicts of interest. 940P OVERALL SURVIVAL BENEFIT WITH SIPULEUCEL-T BY BASELINE PROSTATE-SPECIFIC ANTIGEN (PSA): AN EXPLORATORY ANALYSIS FROM THREE PHASE 3 TRIALS P. Kantoff 1 , G. Chodak 2 , R.B. Sims 3 , J.B. Whitmore 4 , P. Schellhammer 5 1 Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, UNITED STATES OF AMERICA, 2 Oncology, Weiss Memorial Hospital, Chicago, IL, UNITED STATES OF AMERICA, 3 Clinical Affairs, Dendreon Corporation, Seattle, WA, UNITED STATES OF AMERICA, 4 Biometrics, Dendreon, Seattle, WA, UNITED STATES OF AMERICA, 5 Urology, Eastern Virginia Medical School / Urology of Virginia, Virginia, VA, UNITED STATES OF AMERICA Introduction and objective: Sipuleucel-T is an autologous cellular immunotherapy approved for the treatment of asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer (mCRPC) based on improved overall survival (OS) in the pivotal phase 3 IMPACT trial (NCT00065442). In a subgroup analysis of pooled data from three Phase 3 trials of sipuleucel-T in mCRPC, baseline PSA was found to be the most significant predictive factor for OS. To further investigate the impact of baseline PSA levels on outcomes following sipuleucel-T, we conducted an exploratory analysis of patients (pts) from three Phase 3 trials. Methods: The analysis included all 737 randomized pts from three Phase 3 trials (D9901, D9902A and IMPACT). Pts were categorized by baseline PSA quartile (Table), as well as by ECOG PS, and median for other baseline prognostic variables (i.e. lactate dehydrogenase [LDH], alkaline phosphatase [ALP], and hemoglobin [Hgb]). Median OS and hazard ratio (HR) were estimated using Kaplan-Meier and Cox models, respectively. Results: HR values suggest consistent treatment effect in all subsets, although there is inadequate power to show statistical significance within each quartile. There was a trend toward an increased magnitude of treatment benefit in pts with a lower baseline PSA (Table). Results for other baseline prognostic variables also suggest a trend toward greater benefit with better prognostic features. However, results for baseline Hgb indicated an opposite trend Conclusions: Although not powered for statistical significance, this analysis supports a consistent OS benefit with sipuleucel-T across PSA quartiles in patients enrolled in Phase 3 trials. The greater benefit with lower baseline PSA suggests that pts with less advanced disease may benefit more from sipuleucel-T. Baseline PSA (ng/mL) ≤22.3 >22.3– ≤ 49.9 >49.9– ≤ 137.8 >137.8 n Median OS, mos 184 184 184 183 Sipuleucel-T 41.2 25.9 20.6 15.1 Control 26.7 22.0 14.8 13.5 Difference 14.5 3.9 5.8 1.6 HR; 95% CI 0.48; 0.32–0.73 0.76; 0.53–1.11 Annals of Oncology 0.67; 0.47–0.95 0.88; 0.62–1.25 Disclosure: P. Kantoff: Advisory boards for Dendreon Corporation G. Chodak: Stock ownership in Amgen; Advisory boards for Dendreon Corporation and Janssen; Honoraria for Dendreon Corporation and Amgen. R.B. Sims: Stock ownership and employee of Dendreon Corporation. J.B. Whitmore: Employee of Dendreon Corporation; Stock ownership in Dendreon Corporation and Amgen, P. Schellhammer: Honoraria for Dendreon Corporation 941P IMPACT OF SALVAGE THERAPY WITH APC8015F ON THE OVERALL SURVIVAL (OS) BENEFIT ACHIEVED WITH SIPULEUCEL-T IN THREE PHASE 3 STUDIES OF METASTATIC CASTRATE-RESISTANT PROSTATE CANCER (MCRPC) D.J. George 1 , L.G. Gomella 2 , T. Devries 3 , J.B. Whitmore 3 , M.W. Frohlich 4 , C. Nabhan 5 1 Medicine, Duke University, Durham, NC, UNITED STATES OF AMERICA, 2 Urology, Thomas Jefferson University, Philadelphia, PA, UNITED STATES OF AMERICA, 3 Biometrics, Dendreon, Seattle, WA, UNITED STATES OF AMERICA, 4 Clinical Affairs, Dendreon Corporation, Seattle, WA, UNITED STATES OF AMERICA, 5 Hematology and Medical Oncolgoy, Advocate Lutheran General Hospital, Park Ridge, IL, UNITED STATES OF AMERICA Background: Sipuleucel-T is an autologous cellular immunotherapy approved for asymptomatic or minimally symptomatic mCRPC. Three Phase 3 sipuleucel-T trials (D9901, D9902A, IMPACT) allowed control patients (pts) to receive salvage treatment with an autologous product derived from previously frozen cells (APC8015F). We previously reported that APC8015F demonstrated no deleterious effect. Control pts who received APC8015F had more favorable baseline prognostic features; however, after adjusting for these imbalances, APC8015F appears to have prolonged OS in control pts, potentially reducing the observed sipuleucel-T treatment effect. This exploratory integrated analysis estimates the OS benefit conferred by sipuleucel-T, adjusting for APC8015F in control pts. Methods: A rank-preserving structural failure time (RPSFT) model was used to estimate control arm OS if treatment with APC8015F had not occurred. This allows estimation of the treatment effect of sipuleucel-T, adjusting for salvage effect. Results: Median OS from randomization in the three pooled trials was 25.4 months with sipuleucel-T (n = 488) and 21.5 months with control (n = 249). Of the control arm pts, 165 (66.3%) subsequently received APC8015F. Median OS from randomization in the control population was 23.6 months for pts receiving APC8015F and 12.7 months for those who did not. Using the RPSFT model, and assuming APC8015F was as effective as sipuleucel-T, the estimate of median OS for control pts was 17.3 months, representing an 8.1 month median increase in OS with sipuleucel-T. Results from extensions of the RPSFT model, where APC8015F is assumed to have less treatment effect than sipuleucel-T, will be presented. Conclusions: These analyses estimate a median OS benefit for sipuleucel-T between 3.9 and 8.1 months, assuming that APC8015F had either no efficacy or comparable efficacy to sipuleucel-T, respectively. These results suggest a possible greater treatment effect of sipuleucel-T than was reported in the three Phase 3 studies. Future studies should account for potential crossover treatment bias as this may diminish estimates of OS benefit. Disclosure: D.J. George: Consultant, Investigator, or Lecturer for the following companies: Astellas, Bayer, BMS, Dendreon, Exelixis, Genentech/Roche, GSK, Ipsen, Jansen, Medivation, Novartis, Pfizer, Sanofi, Viamet, L.G. Gomella: Consultant/ Advisor and Clinical Trials for Dendreon, T. Devries: Employee and Stockholder of Dendreon. J.B. Whitmore: Employee and Stockholder of Dendreon. M.W. Frohlich: Employee and Stockholder of Dendreon. C. Nabhan: I am on the speakers bureau of Dendreon and have received honoraria for speaking engagements. ix310 | Abstracts Volume 23 | Supplement 9 | September 2012
Page 1 and 2:
Annals of Oncology www.annonc.oxfor
Page 3 and 4:
subscriptions A subscription to Ann
Page 6 and 7:
Annals of Oncology Official Journal
Page 8 and 9:
The European Society for Medical On
Page 10 and 11:
Audit Committee Chair: Fortunato Ci
Page 12 and 13:
Familial cancer Judith Balmaña, Ba
Page 14 and 15:
ESMO 2012 Congress Travel Grants 47
Page 16 and 17:
Exhibitors The following companies
Page 18 and 19:
ESMO Fellowships, 1989-2011 The Eur
Page 20:
Ondrej Gojis, Czech Republic 2008-2
Page 23 and 24:
abstracts hpv biology and implicati
Page 25 and 26:
abstracts the characterization of l
Page 27 and 28:
abstracts description of intra-tumo
Page 29 and 30:
prevent cell death. It is anticipat
Page 31 and 32:
22IN TARGETING THE HOST IN TNBC G.
Page 33 and 34:
abstracts a paradigm shift in early
Page 35 and 36:
abstracts how can medical oncologis
Page 37 and 38:
feasibility), but by how high the c
Page 39 and 40:
abstracts re-inventing the medical
Page 41 and 42:
abstracts emerging diagnostic and t
Page 43 and 44:
abstracts biologically based treatm
Page 45 and 46:
abstracts molecular targets in mali
Page 47 and 48:
abstracts melanoma therapy: from fr
Page 49 and 50:
diagnosis and can also be used for
Page 51 and 52:
analysis at 11 months median follow
Page 53 and 54:
mouse model of Kras mutant NSCLC. I
Page 55 and 56:
abstracts subtyping soft tissue sar
Page 57 and 58:
abstracts key topics in supportive
Page 59 and 60:
ESMO-CSCO Joint Symposium: Building
Page 61 and 62:
ESMO-EANM-ESR Joint Symposium: Imag
Page 63 and 64:
ESMO-ESTRO Joint Symposium: Innovat
Page 65 and 66:
ESMO-MASCC Joint Symposium: Integra
Page 67 and 68:
ESO Society Symposium: Celebrating
Page 69 and 70:
Results: TIMP-1 expression was incr
Page 71 and 72:
will benefit from this targeted the
Page 73 and 74:
cytomegalovirus (CMV). Analysis of
Page 75 and 76:
functional consequences of Endoglin
Page 77 and 78:
elationship between the ROR score,
Page 79 and 80:
183P EPIDERMAL GROWTH FACTOR RECEPT
Page 81 and 82:
Plasma adiponectin level on the pre
Page 83 and 84:
Table: 198P PFS OS Median, mo HR Me
Page 85 and 86:
204P EVALUATION OF PTEN AND PIK3CA
Page 87 and 88:
Material and methods: We searched P
Page 89 and 90:
Results: The median concentration o
Page 91 and 92:
Table: 226P Methods: Pts were rando
Page 93 and 94:
However, additional analysis sugges
Page 95 and 96:
number of biomarkers have been trie
Page 97 and 98:
Table: 248O 249PD PROTEOMIC PREDICT
Page 99 and 100:
Conclusions: BW and serum Ctrough o
Page 101 and 102:
261P BREAST CANCER SUBTYPES AND OUT
Page 103 and 104:
90 mg/m2-cyclophophamide 600 mg/m2
Page 105 and 106:
to 9 weeks after dosing. Trastuzuma
Page 107 and 108:
Patients and methods: We reviewed d
Page 109 and 110:
sector patients. The aim of this st
Page 111 and 112:
Linear Logistic Model with Relaxed
Page 113 and 114:
Results: The median CTC fold change
Page 115 and 116:
312: Table: Chemotherapy uptake wit
Page 117 and 118:
abstracts breast cancer, locally ad
Page 119 and 120:
Results: 8 trials (2092 pts) with 1
Page 121 and 122:
absolute difference of median value
Page 123 and 124:
Novartis, Genentech, and sanofi-ave
Page 125 and 126:
Results: Three RCTs with 1023 patie
Page 127 and 128:
collected from all patients for det
Page 129 and 130:
355P FIRST REPORT OF LONG-TERM RESP
Page 131 and 132:
361P A RETROSPECTIVE ANALYSIS OF PL
Page 133 and 134:
publications and aggregated in a me
Page 135 and 136:
Thus the primary aim to target BCSC
Page 137 and 138:
383 WHY DO WOMEN WITH BREAST CANCER
Page 139 and 140:
Results: We evaluated 76 pts with M
Page 141 and 142:
more than 6 cycles of capecitabine.
Page 143 and 144:
406TiP PHASE II TRIAL OF PRIMARY SY
Page 145 and 146:
abstracts CNS tumors 410O CONDITION
Page 147 and 148:
Conclusions: Our data suggested tha
Page 149 and 150:
Conclusions: As in other cancer typ
Page 151 and 152:
432 GAMMA KNIFE RADIOSURGERY AS A M
Page 153 and 154:
abstracts developmental therapeutic
Page 155 and 156:
1PR), but no responses were seen in
Page 157 and 158:
RO and Cd, as well as PD data for c
Page 159 and 160:
and vulvar Ca), and 11 SDs were obs
Page 161 and 162:
knowing HLA-A status double-blindly
Page 163 and 164:
Acquired-resistance to EGFR inhibit
Page 165 and 166:
474P PHASE 1 STUDY OF THE SELECTIVE
Page 167 and 168:
TST is active in breast and gastric
Page 169 and 170:
Treatment-induced shedding of circu
Page 171 and 172:
Methods: Either co-cultures of peri
Page 173 and 174:
501 PRECLINICAL DATA INVESTIGATING
Page 175 and 176:
509TiP LUX-LUNG 8: A RANDOMIZED, OP
Page 177 and 178:
(P = 0.64). Synchronous BBC was sig
Page 179 and 180:
abstracts gastrointestinal tumors,
Page 181 and 182:
Disclosure: M. Lee: I am an employe
Page 183 and 184:
plus intravenous Bev(7.5mg/kg q 21d
Page 185 and 186:
anti-EGFR treatment. The present st
Page 187 and 188:
patients harboring a T/T genotype t
Page 189 and 190:
551P ADJUVANT CHEMOTHERAPY (AC) USE
Page 191 and 192:
experienced significantly more ≥
Page 193 and 194:
functioning scales. Exploratory ana
Page 195 and 196:
oxaliplatin (100 mg/m 2 )/raltitrex
Page 197 and 198:
572P PANERB STUDY: WHICH CATEGORY O
Page 199 and 200:
Results: 92/114 patients were preop
Page 201 and 202:
585P CHANGES IN THE INTESTINAL ENVI
Page 203 and 204:
592P PHASE II TRIAL OF COMBINED CHE
Page 205 and 206:
minutes. In a previous study, 30-mi
Page 207 and 208:
Patients and methods: Chemotherapy-
Page 209 and 210:
612P ARE PATIENTS WITH RESECTABLE R
Page 211 and 212:
Conclusions: AMPK and ACC activatio
Page 213 and 214:
of surgical monotherapy in patients
Page 215 and 216:
Table: 632 633 AFLIBERCEPT/FOLFIRI
Page 217 and 218:
factors play the determining role i
Page 219 and 220:
Abstract withdrawn in exceptional c
Page 221 and 222:
were respectively 10.6 vs 8.5 vs 3.
Page 223 and 224:
Results: 20 gastrointestinal cancer
Page 225 and 226:
abstracts gastrointestinal tumors,
Page 227 and 228:
Day 8. A second identical course wa
Page 229 and 230:
proven in stage I GC. The aim of th
Page 231 and 232:
Conclusions: Longer OS to FOLFOX wa
Page 233 and 234:
692P PRELIMINARY SAFETY DATA FROM A
Page 235 and 236:
subgroup. Taking into consideration
Page 237 and 238:
Results: Three years of adjuvant im
Page 239 and 240:
considered sufficient to give an 80
Page 241 and 242:
721P FIRST-LINE TREATMENT WITH FOLF
Page 243 and 244:
after Gem-based therapy. The additi
Page 245 and 246:
735P RADIOGRAPHIC PARAMETERS IN PRE
Page 247 and 248:
validate the revised AJCC 7th stagi
Page 249 and 250:
Results: Among 862 MM we identified
Page 251 and 252:
Results: Frequently reported advers
Page 253 and 254:
gastric cancer patients with CNS me
Page 255 and 256:
discriminate the prognosis of HCC p
Page 257 and 258:
prospective, non-interventional stu
Page 259 and 260: abstracts genitourinary tumors, non
Page 261 and 262: 787O EXTERNAL VALIDATION OF THE ASS
Page 263 and 264: patient preference for P over S, an
Page 265 and 266: 798PD OPEN-LABEL PHASE II TRIAL OF
Page 267 and 268: Hb, PS and LM. Median PFS for patie
Page 269 and 270: may have led to reduced dose and sh
Page 271 and 272: Results: 1,622 patients were identi
Page 273 and 274: RCC) was designed to address an unm
Page 275 and 276: Patients and methods: This is a sin
Page 277 and 278: treatment at week 4, and week 12 by
Page 279 and 280: effective in second or further line
Page 281 and 282: Conclusions: In pts with RCC treate
Page 283 and 284: using Drug inCode ® pharmacogeneti
Page 285 and 286: Table: 857P standard, but is not av
Page 287 and 288: efused HDCT. Of 23 patients, 20 com
Page 289 and 290: we identified 49 and 220 patients w
Page 291 and 292: 879 TREATMENT OF PATIENTS WITH META
Page 293 and 294: Median overall survival (OS) was 26
Page 295 and 296: abstracts Genitourinary tumors, pro
Page 297 and 298: and week 13 BPI-SF Q3 scores), 28%
Page 299 and 300: Working Group (PCWG)-2 guidelines r
Page 301 and 302: atio HR 0.39; CI 0.18, 0.83, p = 0.
Page 303 and 304: We observed tumor responses and pro
Page 305 and 306: Here we report emerging data from t
Page 307 and 308: 928P LHRH AGONIST-INDUCED SUPPRESSI
Page 309: Disclosure: S. Oudard: Has acted as
Page 313 and 314: 945 BONE TURNOVER MARKERS AND POTEN
Page 315 and 316: 952 SEQUENTIAL ANDROGEN DEPRIVATION
Page 317 and 318: managed in a multidisciplinary (MD)
Page 319 and 320: or hypercalcemia at screening; prio
Page 321 and 322: meeting. The prevalence of LGSC is
Page 323 and 324: Table: 975PD Continued AMG 386 + pa
Page 325 and 326: physicians in the U.S. and Europe.
Page 327 and 328: 989P PHASE II STUDY OF COMBINATION
Page 329 and 330: elated with stage, nodal involvemen
Page 331 and 332: 1004P CASE CONTROL STUDY ON TWO DIF
Page 333 and 334: eight patients who had infertility
Page 335 and 336: abstracts head and neck cancer 1016
Page 337 and 338: same CT/RT; Arm B2: 3 cycles of ind
Page 339 and 340: induction chemotherapy in the treat
Page 341 and 342: patients. We have developed a rando
Page 343 and 344: evaluated by the screening instrume
Page 345 and 346: morbidities that radiation would le
Page 347 and 348: Conclusions: Through adequate selec
Page 349 and 350: abstracts hematological malignancie
Page 351 and 352: anthracyclines in vitro. A favorabl
Page 353 and 354: 1076P RITUXIMAB PLUS SUBCUTANEOUS C
Page 355 and 356: than the standard target of ≥2.5
Page 357 and 358: Patients: From November 2002 to May
Page 359 and 360: lymphadenopathy and multiple cutane
Page 361 and 362:
prospective non-interventional stud
Page 363 and 364:
Funding: GSK Biologicals Disclosure
Page 365 and 366:
survival rates of 13-25% (Prieto et
Page 367 and 368:
high response rates and prolonged p
Page 369 and 370:
GlaxoSmithKline, Merck Sharp & Dohm
Page 371 and 372:
advisor for Merck Sharp & Dohme, an
Page 373 and 374:
or cutaneous melanoma. A survival u
Page 375 and 376:
systemic therapy or were intolerant
Page 377 and 378:
abstracts neuroendocrine tumors and
Page 379 and 380:
morbidity, with G3 tumors behaving
Page 381 and 382:
pts. Poorly differentiated endocrin
Page 383 and 384:
Adenocarcinoma was present in 25 pa
Page 385 and 386:
Method: Endobronchial ultrasound gu
Page 387 and 388:
widely used by single agent or plat
Page 389 and 390:
disease after surgery were treated
Page 391 and 392:
stage IIIA NSCLC, EML4-ALK fusion-p
Page 393 and 394:
1200P CONCOMITANT CHEMORADIATION GI
Page 395 and 396:
Patients and methods: The study was
Page 397 and 398:
months (95% CI:13-25). The PFS and
Page 399 and 400:
maintenance therapy had favourable
Page 401 and 402:
abstracts non-small cell lung cance
Page 403 and 404:
Ingelheim, GSK Biologicals (compens
Page 405 and 406:
1234PD RANDOMIZED PHASE III TRIAL O
Page 407 and 408:
GlaxoSmithKline (myself, compensate
Page 409 and 410:
1243P IDENTIFICATION OF MICRORNA (M
Page 411 and 412:
N-arm n=34 P-arm n=32 All n=66 Male
Page 413 and 414:
1255P POPULATION BASED EVALUATION O
Page 415 and 416:
1262P DISTINCT SPREAD OF EGFR MUTAT
Page 417 and 418:
1268P VISUAL DISTURBANCES IN PATIEN
Page 419 and 420:
MERCK SERONO: Advisor, speaker in s
Page 421 and 422:
Conclusions: These data from SAiL a
Page 423 and 424:
NSCLC diagnosis and time of BM diag
Page 425 and 426:
1291P PHASE I/II DOSE-FINDING STUDY
Page 427 and 428:
Network utilization of WBCGF in the
Page 429 and 430:
1303P COST EFFECTIVENESS OF PEMETRE
Page 431 and 432:
Results: The patients’ characteri
Page 433 and 434:
EGFR mut at exons 18, 19, 21, and K
Page 435 and 436:
Methods: EML4-ALK fusion was screen
Page 437 and 438:
Results: The median survival time (
Page 439 and 440:
enefit from sustained EGFR blockade
Page 441 and 442:
epresented by 19 pts (32%) female,
Page 443 and 444:
and at least one prior course of ch
Page 445 and 446:
Methods: NSCLC patients with radiog
Page 447 and 448:
1367TiP LONG-TERM ERLOTINIB THERAPY
Page 449 and 450:
Austria, Czech Republic, Finland, G
Page 451 and 452:
were every 6 weeks (wk) (S1), every
Page 453 and 454:
Advantage enrollees (83% vs. 25%) [
Page 455 and 456:
Results: Based on 10,000 simulation
Page 457 and 458:
cancer tumors 12%, Germ cell tumor
Page 459 and 460:
Material and methods: 50 lung cance
Page 461 and 462:
1414TiP IMPLEMENTATION OF CANCER RE
Page 463 and 464:
abstracts palliative care 1422O EFF
Page 465 and 466:
Method and results: A total of 317
Page 467 and 468:
1436P SURVEY ON MODELS OF INTEGRATI
Page 469 and 470:
care unit (PCU) at the National Can
Page 471 and 472:
Characteristic No. % Total 63 1 st
Page 473 and 474:
hysterectomised-9.10% and cervix ca
Page 475 and 476:
abstracts psycho-oncology 1462PD IN
Page 477 and 478:
events, tumour response, and surviv
Page 479 and 480:
abstracts sarcoma 1477O ADHESION TO
Page 481 and 482:
1481PD A PHASE II STUDY OF DOVITINI
Page 483 and 484:
1488P ORGANISATION OF SARCOMA PATIE
Page 485 and 486:
Patients and methods: From August 2
Page 487 and 488:
chemotherapy respectively. At a med
Page 489 and 490:
of this group Those with relapsed d
Page 491 and 492:
1515 PREDICTORS OF SURVIVAL IN ADOL
Page 493 and 494:
abstracts small cell lung cancer an
Page 495 and 496:
emaining receiving either CAV or to
Page 497 and 498:
1533P EXPRESSION OF WILM⍰TUMOUR G
Page 499 and 500:
more than 3 months after first line
Page 501 and 502:
lower recurrence rate of NE. Pegfil
Page 503 and 504:
egimens (HR = 2.5, p < 0.001). Phys
Page 505 and 506:
1561P PREDICTIVE DIAGNOSTICS FOR RE
Page 507 and 508:
Methods: A prospective multicentre
Page 509 and 510:
Table: 1574P Pharmacokinetic parame
Page 511 and 512:
Novartis and unrestricted research
Page 513 and 514:
studies have shown that chemotherap
Page 515 and 516:
(Grade 1) and moderate to severe (G
Page 517 and 518:
declined to relatively lower level
Page 519 and 520:
1609P PHYSICAL ACTIVITY (PA) AND PH
Page 521 and 522:
patients were admitted to the oncol
Page 523 and 524:
Dicarbamin 100 mg/day on day 5 befo
Page 525 and 526:
Results: Anemia was detected in 83.
Page 527 and 528:
important to carry out randomized s
Page 529 and 530:
abstracts translational research 16
Page 531 and 532:
expression. Then, we analyzed PB sa
Page 533 and 534:
Table: 1657P TH BV + TH HR (95% CI)
Page 535 and 536:
BRAF mutations. Circulating free DN
Page 537 and 538:
1671P PHASE I CLINICAL TRIAL OF CAN
Page 539 and 540:
1678P PREDICTIVE VALUE OF TWO PHENO
Page 541 and 542:
theorized that the PI3K/AKT pathway
Page 543 and 544:
Material and methods: 101 patients
Page 545 and 546:
overexpressing and 232 had triple n
Page 547 and 548:
author index author index A Aamdal
Page 549 and 550:
author index Badran A. ix288 (874)
Page 551 and 552:
author index Bösmüller H. ix209 (
Page 553 and 554:
author index Chen A. ix319 (966O) C
Page 555 and 556:
author index De Droogh E. ix452 (13
Page 557 and 558:
author index Esposito G. ix209 (618
Page 559 and 560:
author index Geiges G. ix306 (930P)
Page 561 and 562:
author index Hartono S. ix70 (155P)
Page 563 and 564:
author index Iwasaki H. ix542 (1694
Page 565 and 566:
author index Kodaira M. ix90 (228P)
Page 567 and 568:
author index Lichtensztejn D. ix350
Page 569 and 570:
author index Martinez A. ix496 (153
Page 571 and 572:
author index Morishita N. ix432 (13
Page 573 and 574:
author index Okamoto N. ix432 (1320
Page 575 and 576:
author index Piau S. ix456 (1401P)
Page 577 and 578:
author index Rodríguez Rodríguez
Page 579 and 580:
author index Scoggins C.R. ix371 (1
Page 581 and 582:
author index Stern L. ix272 (823P)
Page 583 and 584:
author index Trypaki M. ix429 (1308
Page 585 and 586:
author index Whitmore J.B. ix310 (9
Page 587 and 588:
subject index subject index A AAV-H
Page 589 and 590:
subject index ix115 (316TiP), ix116
Page 591 and 592:
subject index diffuse large B-cell
Page 593 and 594:
subject index (1033P), ix340 (1036P
Page 595 and 596:
subject index medical information,
Page 597 and 598:
subject index (612P), ix214 (633),
Page 599 and 600:
subject index RCC, ix274 (830P) re-
Page 601 and 602:
subject index TR-FRET, ix84 (206P)
Page 603 and 604:
drug index drug index 1248P, 1250P,
Page 605 and 606:
translational research index transl
Page 607 and 608:
Page 609:
show all

Download the ESMO 2012 Abstract Book - Oxford Journals

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?